Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 9, Issue 9, Pages 803-811Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2013.828876
Keywords
allergic rhinitis; azelastine hydrochloride; clinical trials; fluticasone propionate; intranasal; randomized
Categories
Funding
- MEDA
- Alcon
- Sunovian
- TEVA
- Allergan
Ask authors/readers for more resources
This review presents the pharmacology, clinical efficacy and safety of MP29-02 (Dymista (R)), a unique product for the treatment of allergic rhinitis. Allergic rhinitis is often thought of more as a nuisance than a meaningful medical condition, and the health impact of allergic rhinitis can easily be underestimated. As a result, allergic rhinitis can be undertreated, expectations for relief may not be met, and patients may be left dissatisfied and non-compliant with their medications. MP29-02 is the only currently available allergic rhinitis medication to provide potent early-phase histamine-receptor blocking and long-term anti-inflammatory effects in a single intranasal formulation and delivery system that represents an advance in the therapy of allergic rhinitis, in particular for patients with moderate-to-severe disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available